171 related articles for article (PubMed ID: 17392871)
1. Rapid regression of disc and retinal neovascularization in a case of Eales disease after intravitreal bevacizumab.
Kumar A; Sinha S
Can J Ophthalmol; 2007 Apr; 42(2):335-6. PubMed ID: 17392871
[No Abstract] [Full Text] [Related]
2. Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin).
Isaacs TW; Barry C
Clin Exp Ophthalmol; 2006 Nov; 34(8):802-3. PubMed ID: 17073910
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab treatment of macular edema due to optic disc vasculitis.
Erdurman FC; Durukan AH; Mumcuoğlu T; Hürmeriç V
Ocul Immunol Inflamm; 2009; 17(1):56-8. PubMed ID: 19294575
[TBL] [Abstract][Full Text] [Related]
4. Rapid regression of disc neovascularization in a patient with proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab.
Bakri SJ; Donaldson MJ; Link TP
Eye (Lond); 2006 Dec; 20(12):1474-5. PubMed ID: 16680105
[No Abstract] [Full Text] [Related]
5. Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy.
Siqueira RC; Costa RA; Scott IU; Cintra LP; Jorge R
Acta Ophthalmol Scand; 2006 Dec; 84(6):834-5. PubMed ID: 17083555
[No Abstract] [Full Text] [Related]
6. Intravitreal bevacizumab for peripapillary classic subretinal neovascularization.
Spandau UH; Jonas JB
Acta Ophthalmol Scand; 2007 May; 85(3):340-1. PubMed ID: 17488467
[No Abstract] [Full Text] [Related]
7. Progression of macular ischemia following intravitreal bevacizumab.
Sabet-Peyman EJ; Heussen FM; Thorne JE; Casparis H; Patel SJ; Do DV
Ophthalmic Surg Lasers Imaging; 2009; 40(3):316-8. PubMed ID: 19485300
[TBL] [Abstract][Full Text] [Related]
8. The effects of intravitreous bevacizumab on retinal neovascular membrane and normal capillaries in rabbits.
Ameri H; Chader GJ; Kim JG; Sadda SR; Rao NA; Humayun MS
Invest Ophthalmol Vis Sci; 2007 Dec; 48(12):5708-15. PubMed ID: 18055823
[TBL] [Abstract][Full Text] [Related]
9. An unusual optic disc neovascularization in a case of intermediate uveitis associated with multiple sclerosis.
Karagiannis DA; Ladas ID
Eur J Ophthalmol; 2008; 18(6):1020-2. PubMed ID: 18988181
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal bevacizumab in inflammatory ocular neovascularization.
Mansour AM; Mackensen F; Arevalo JF; Ziemssen F; Mahendradas P; Mehio-Sibai A; Hrisomalos N; Lai TY; Dodwell D; Chan WM; Ness T; Banker AS; Pai SA; Berrocal MH; Tohme R; Heiligenhaus A; Bashshur ZF; Khairallah M; Salem KM; Hrisomalos FN; Wood MH; Heriot W; Adan A; Kumar A; Lim L; Hall A; Becker M
Am J Ophthalmol; 2008 Sep; 146(3):410-416. PubMed ID: 18619571
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal bevacizumab (Avastin) as a treatment of the neovascular complications of laser-induced chorioretinal anastomosis for nonischaemic central retinal vein occlusion.
Fong KC; Barry C; McAllister IL
Clin Exp Ophthalmol; 2009 Jul; 37(5):485-9. PubMed ID: 19624345
[TBL] [Abstract][Full Text] [Related]
12. Vanishing disc neovascularization following intravitreal bevacizumab (avastin) injection.
Friedlander SM; Welch RM
Arch Ophthalmol; 2006 Sep; 124(9):1365. PubMed ID: 16966642
[No Abstract] [Full Text] [Related]
13. Resolution of subretinal haemorrhage and fluid after intravitreal bevacizumab in aggressive peripapillary subretinal neovascularization.
Soliman W; Lund-Andersen H; Larsen M
Acta Ophthalmol Scand; 2006 Oct; 84(5):707-8. PubMed ID: 16965507
[No Abstract] [Full Text] [Related]
14. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.
Avery RL; Pearlman J; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ; Wendel R; Patel A
Ophthalmology; 2006 Oct; 113(10):1695.e1-15. PubMed ID: 17011951
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal injection of bevacizumab in Eales disease.
Küçükerdönmez C; Akova YA; Yilmaz G
Ocul Immunol Inflamm; 2008; 16(1):63-5. PubMed ID: 18379947
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab (Avastin) in idiopathic retinitis, vasculitis, aneurysms and neuroretinitis.
Akesbi J; Brousseaud FX; Adam R; Rodallec T; Nordmann JP
Acta Ophthalmol; 2010 Mar; 88(2):e40-1. PubMed ID: 19508455
[No Abstract] [Full Text] [Related]
17. Rapid regression of extensive retinovitreal neovascularization secondary to branch retinal vein occlusion after a single intravitreal injection of bevacizumab.
Ahmadieh H; Moradian S; Malihi M
Int Ophthalmol; 2005; 26(4-5):191-3. PubMed ID: 17286185
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy.
Mason JO; Nixon PA; White MF
Am J Ophthalmol; 2006 Oct; 142(4):685-8. PubMed ID: 17011869
[TBL] [Abstract][Full Text] [Related]
19. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment.
Avery RL
Retina; 2006 Mar; 26(3):352-4. PubMed ID: 16508438
[No Abstract] [Full Text] [Related]
20. Combined photodynamic therapy and intravitreal bevacizumab as primary treatment for subretinal neovascularization associated with type 2 idiopathic macular telangiectasia.
Rishi P; Rishi E; Shroff D
Indian J Ophthalmol; 2009; 57(3):241-2. PubMed ID: 19384026
[No Abstract] [Full Text] [Related]
[Next] [New Search]
